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Abstract
Introduction Women who carry mutations in BRCA1 and
BRCA2 have a substantially increased risk of developing breast
cancer as compared with the general population. However, risk
estimates range from 20 to 80%, suggesting the presence of
genetic and/or environmental risk modifiers. Based on extensive
in vivo and in vitro studies, one important pathway for breast
cancer pathogenesis may be the insulin-like growth factor (IGF)
signaling pathway, which regulates both cellular proliferation
and apoptosis. BRCA1 has been shown to directly interact with
IGF signaling such that variants in this pathway may modify risk
of cancer in women carrying BRCA mutations. In this study, we
investigate the association of variants in genes involved in IGF
signaling and risk of breast cancer in women who carry
deleterious BRCA1 and BRCA2 mutations.
Methods A cohort of 1,665 adult, female mutation carriers,
including 1,122 BRCA1 carriers (433 cases) and 543 BRCA2
carriers (238 cases) were genotyped for SNPs in IGF1, IGF1
receptor (IGF1R), IGF1 binding protein (IGFBP1, IGFBP2,Page 1 of 12
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proportional hazards regression was used to model time from
birth to diagnosis of breast cancer for BRCA1 and BRCA2
carriers separately. For linkage disequilibrium (LD) blocks with
multiple SNPs, an additive genetic model was assumed; and for
single SNP analyses, no additivity assumptions were made.
Results Among BRCA1 carriers, significant associations were
found between risk of breast cancer and LD blocks in IGF1R
(global P = 0.011 for LD block 2 and global P = 0.012 for LD
block 11). Among BRCA2 carriers, an LD block in IGFBP2
(global P = 0.0145) was found to be associated with the time to
breast cancer diagnosis. No significant LD block associations
were found for the other investigated genes among BRCA1 and
BRCA2 carriers.
Conclusions This is the first study to investigate the role of
genetic variation in IGF signaling and breast cancer risk in
women carrying deleterious mutations in BRCA1 and BRCA2.
We identified significant associations in variants in IGF1R and
IRS1 in BRCA1 carriers and in IGFBP2 in BRCA2 carriers.
Although there is known to be interaction of BRCA1 and IGF
signaling, further replication and identification of causal
mechanisms are needed to better understand these
associations.
Introduction
Women who carry mutations in the BRCA1 and BRCA2
genes have a substantially increased risk of developing breast
cancer and ovarian cancers as compared with the general
population. Estimates of the age-specific risk attributable to
mutations at these loci vary depending on the ascertainment
scheme. The cumulative risks of breast cancer by age 70 were
estimated to be 65% and 45% for BRCA1 and BRCA2 muta-
tion carriers, respectively, in a meta-analysis of population-
based studies [1] - as compared with 56 to 80% for BRCA1
and BRCA2 mutation carriers, respectively, in analyses based
on families with multiple affected individuals [2-5].
Among BRCA1 and BRCA2 mutation carriers, there is con-
siderable variability in both the age at diagnosis and the inci-
dence of breast and ovarian cancers, even among women who
carry the same BRCA1 and BRCA2 mutation [6-8]. These risk
estimates not only show that such women are at extremely
high risk for developing breast cancer, but also illustrate that
there is great variability in the time to breast cancer diagnosis
among carriers. These observations are consistent with the
hypothesis that the breast cancer risk in mutation carriers is
modified by other genetic and/or environmental factors. There
are published reports of genetic modifiers of cancer risk in
mutation carriers (for example, variants in AIB1 in BRCA1; var-
iants in RAD51, FGFR2 and MAP3K1 in BRCA2; and variants
in TNRC9 in BRCA1 and BRCA2) [9-13].
One important pathway for cancer pathogenesis may be the
insulin-like growth factor (IGF) signaling pathway, as it regu-
lates both cellular proliferation and apoptosis. Extensive evi-
dence from in vivo and in vitro model systems and human
studies (reviewed in [14-16]) supports a major role for the
IGF1 signaling pathway in breast cancer pathogenesis. Mam-
mographic density, a strong risk factor for breast cancer, has
been positively associated with the ratio of IGF1 to insulin-like
growth factor binding protein (IGFBP)-3 in premenopausal
women [17], and has been shown to modify the breast cancer
risks in BRCA1 and BRCA2 mutation carriers [18]. BRCA1
has been shown to directly affect IGF1 signaling. In multiple
experimental systems, including primary mammary tumors, cul-
tured human cells, and Brca1-deficient mice, Shukla and col-
leagues showed that BRCA1 deficiency resulted in increased
expression of insulin-like growth factor receptor substrate 1
(IRS1), insulin-like growth factor-1 receptor (IGF1R), IGFBP2,
and increased levels of serum IGF1 [19]. In another study
investigating IGF1R levels in breast tumors, there were signif-
icantly higher levels of IGF1R in tumors from BRCA1 mutation
carriers as compared with noncarriers [20].
We hypothesized that genetic variation in IGF signaling will
modify risk of breast cancer in women carrying deleterious
mutations in BRCA1 and BRCA2. In the present study, we
focused on investigating the association of variants in IGF1,
IGFBP1, IGFBP2, IGFBP5, IGF1R, and IRS1 as potential
disease modifiers in mutation carriers of BRCA1 and BRCA2.
Materials and methods
Participants
Women with germline, deleterious mutations in BRCA1 and
BRCA2 were identified in 14 centers in the US, one center in
Canada, and one center in Austria - including Baylor University
Medical Center - Dallas, Beth Israel in Boston, City of Hope,
Creighton University, Dana Farber, Fox Chase Cancer Center,
Georgetown University, the Mayo Clinic, Medical University of
Vienna, North Shore University Health System in Chicago, Uni-
versity of California, Los Angeles, University of California,
Irvine, University of Chicago, University of Pennsylvania, and
Women's College Hospital. The majority of subjects were
recruited from the Medical University in Vienna, Creighton Uni-
versity in Nebraska, the University of Pennsylvania, and the
University of California Irvine (previously at the University of
Utah). All centers are part of the Modifiers and Genetics in
Cancer consortium. All participants were enrolled under Insti-
tutional Review Boards or ethics committee approval at each
participating site.
Women were participating in research studies or were either
physician or self-referred to risk evaluation clinics for genetic
testing, generally because of a strong family history of breast
cancer and/or ovarian cancer. The current study is composed
of a total of 1,665 adult, female mutation carriers, includingPage 2 of 12
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BRCA2 carriers (238 cases and 305 controls). The BRCA1
and BRCA2 mutation status of all subjects was confirmed by
direct mutation testing, with full informed consent under proto-
cols approved by the human subjects review boards at each
institution.
Women were eligible for entry into the study cohort if they
tested positive for a known deleterious mutation in BRCA1 or
BRCA2. Women with BRCA1 and BRCA2 variants of
unknown functional significance were excluded. Women were
excluded if they were missing information on year of birth, par-
ity, menopausal status, and oral contraceptive use, or had
been diagnosed with cancer more than 3 years prior to study
entry. Information about invasive breast cancer, ovarian can-
cer, prophylactic mastectomy and prophylactic oophorectomy
was obtained from medical records, and information on repro-
ductive history and lifestyle habits was obtained by
questionnaire.
SNP genotyping
The 47 SNPs had been selected and genotyped in a previous
case-control study of African-American women. Briefly, a min-
imal set of informative SNPs (tagging SNPs) had been chosen
across each gene to mark the common genetic variation and
to minimize the genotyping costs. Tagging SNP sets were
selected using the TagSNPs program [21] from genotype
data, downloaded directly from the National Institute of Envi-
ronmental Health Sciences Environmental Genome Project
[22]. For the data available at the time, it was not possible to
select tagging SNPs for just a Caucasian population.
Genotyping was performed by the MGB Taqman probe Assay
from Applied Biosystems Inc. (Foster City, CA USA) or the
MGB Eclipse™ probe assay from Nanogen Inc. (San Diego,
CA USA) for all SNPs. Primer and probe sequences are avail-
able from the authors on request.
Specifically, for the MGB Taqman probe assays, the reaction
mix in a final volume of 5 μl included 10 ng genomic DNA, 4.5
pmol each primer, 1.25 pmol each probe, 1 × PCR reaction
buffer (Qiagen, Gaithersburg, MD USA), 2 × Q solution (Qia-
gen), 500 pmol dNTP, and 0.15 units Qiagen DNA polymer-
ase. PCR cycling included 55 cycles of a two-step PCR (95°C
for 15 seconds, and 60°C for 1 minute) after an initial 2 min-
utes at 95°C. PCR plates were read on an ABI PRISM 7900
HT instrument for genotype assignment (Applied Biosystems
Inc.).
Specifically, for the MGB Eclipse™ probe assays, the reaction
mix in a final volume of 5 μl included 10 ng genomic DNA, 0.5
pmol limiting primer, 5 to 10 pmol excess primer, 1 pmol each
probe, 1 × PCR reaction buffer (Qiagen), 2 × Q solution (Qia-
gen), 500 pmol dNTP, and 0.15 units Qiagen DNA polymer-
ase. PCR cycling included 55 cycles of a three-step PCR
(95°C for 10 seconds, 58°C for 20 seconds and 72°C for 20
seconds) after an initial 2 minutes at 95°C.
After completion of PCR, endpoint dissociation melting curves
were generated on the ABI PRISM 7900 HT instrument by
monitoring the fluorescence while heating the reactions from
30°C to 80°C at a 10% rate. An EclipseMeltMacro_v2.328
program (Nanogen Inc., San Diego, CA USA) was employed
to assign the genotype from the dissociation curve data. Dupli-
cates of 22 DNA samples and water controls were genotyped
for quality control. The laboratory technician was blinded as to
whether samples were duplicates, cases, or controls. The
order of the DNA samples on 384-well plates was randomized
in order to ensure balance in study conditions across covari-
ates. Genotyping call rates ranged from 95% to 99% and
duplicate concordance rates were higher than 99%.
Determination of linkage disequilibrium blocks
We recalculated the linkage disequilibrium (LD) blocks for this
study, primarily because we wanted the LD groups to reflect
this predominantly non-Hispanic Caucasian cohort rather than
the mixed sample from which the tagging SNPs were originally
identified. SNPs were grouped according to their adjacent
pairwise LD coefficient (D'). The coefficient was computed
between all adjacent marker pairs within each candidate gene.
In order to account for within-family correlation, multiple outpu-
tation [23] was used to estimate D'. In this case, a single mem-
ber from each family was randomly sampled to create a single
bootstrap sample, from which D' was computed. This process
was repeated to obtain 200 bootstrap samples, yielding an
empirical distribution of D'. An LD block was defined as a set
of contiguous SNPs having D' values exceeding 0.90 between
each contiguous pair of SNPs. The boundary of an LD block
would be defined by a marker pair with D' ≤ 0.9. The LD blocks
for the SNPs within each gene are shown in Additional data
file 1.
Statistical analysis
Breast cancer rates were calculated as the observed number
of breast cancers per total patient time at risk, and were stand-
ardized to the age distribution of the study cohort at the time
of interview [24]. Subjects were considered at risk for breast
cancer from birth until the first occurrence of breast cancer
diagnosis, death, or loss to follow-up. In addition, subjects
were censored in the event that they underwent a bilateral pro-
phylactic surgery of the breasts more than 1 year preceding
the diagnosis of breast cancer. Bilateral prophylactic surgery
of the breasts occurring within 1 year of breast cancer was
considered an event in order to avoid potential biases resulting
from informative censoring.
Covariates that vary with time (ovarian cancer and prophylactic
ovarian surgery) were treated as time dependent in the calcu-
lation of rates. A subject who was diagnosed with ovarian can-
cer therefore contributed time at risk in the non-ovarian cancerPage 3 of 12
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cancer group following the diagnosis. Because subjects were
ascertained primarily from high-risk clinics, there was an over-
sampling of cases. In order to account for potential bias in
cumulative risk estimates due to nonrandom sampling from the
general population, Kaplan-Meier estimates of the cumulative
Table 1
Participant characteristics and incidence of breast cancer diagnosis by BRCA status
BRCA1 BRCA2
Characteristic n Cases Incidence ratea n Cases Incidence ratea
Total 1,122 433 26.94 (19.79, 34.10) 543 238 25.03 (18.71, 31.36)
Raceb
Caucasian (non-Jewish, non-Hispanic) 774 283 26.72 (19.58, 33.86) 381 176 27.70 (20.63, 34.77)
African American 29 14 39.37 (28.13, 50.61) 13 6 25.28 (18.47, 32.09)
Jewish 245 98 24.08 (17.95, 30.22) 119 43 17.39 (13.19, 21.60)
Caucasian Hispanic 35 17 43.97 (30.46, 57.47) 9 5 33.07 (22.50, 43.65)
Other 31 16 38.66 (28.28, 49.05) 19 6 20.68 (15.61, 25.74)
Ovarian cancer
Yes 128 26 20.86 (11.70, 30.01) 30 5 18.90 (8.84, 28.96)
No 994 407 27.78 (20.46, 35.10) 513 233 25.43 (19.10, 31.77)
Prophylactic ovarian surgery
Yes before breast cancer 282 44 24.88 (17.53, 32.23) 108 18 27.64 (19.07, 36.21)
Yes after breast cancer 167 167 -- 99 99 --
No bilateral prophylactic oophorectomy 671 221 28.07 (20.72, 35.42) 336 121 25.29 (18.93, 31.64)
Clinic Site
Medical University Vienna 204 84 39.26 (29.31, 49.21) 62 37 28.19 (20.83, 35.55)
Beth Israel 8 4 30.58 (22.39, 38.76) 15 6 125.51 (35.71, 215.31)
Baylor University Medical Center --Dallas 14 10 69.46 (50.29, 88.63) 1 1 14.59 (10.21, 18.97)
City of Hope 56 25 43.30 (31.79, 54.81) 28 17 54.17 (40.17, 68.18)
Creighton 155 65 28.49 (21.39, 35.59) 40 23 55.87 (42.83, 68.91)
Dana Farber 88 41 36.22 (27.27, 45.18) 32 11 27.20 (21.04, 33.37)
NorthShore University Health System 35 16 26.55 (19.62, 33.47) 21 9 17.77 (13.57, 21.97)
Fox Chase Cancer Center 40 10 14.41 (9.97, 18.86) 28 9 18.18 (13.32, 23.04)
Georgetown University 42 13 21.35 (16.23, 26.47) 16 3 21.64 (16.24, 27.05)
University of California, Los Angeles 43 18 36.95 (25.09, 48.81) 17 7 13.62 (10.03, 17.21)
Mayo Clinic 60 17 18.57 (14.53, 22.61) 31 10 30.38 (24.01, 36.75)
University of Texas Health Science Center at San Antonio 35 17 40.18 (27.33, 53.02) 32 13 11.67 (9.00, 14.34)
University of Chicago 34 15 52.84 (36.66, 69.02) 18 9 18.73 (14.47, 22.98)
University of Pennsylvania 147 56 24.08 (17.37, 30.78) 92 44 51.62 (43.58, 59.66)
University of Utahc 115 30 14.85 (10.70, 19.00) 87 27 27.54 (19.36, 35.72)
Women's College Hospital, Toronto 46 12 16.24 (11.72, 20.76) 23 12 44.56 (33.11, 56.02)
Aged 44.7 ± 11.2 48.1 ± 13
aData presented as incidence per 1,000 women per year (95% confidence interval). Rates have been externally standardized to the age 
distribution of the study cohort at the time of genetic testing. bFive subjects missing race information. cNow at University of California, Irvine. dData 
presented as mean ± standard deviation.Page 4 of 12
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age-specific sampling weights for cases and controls. Sam-
pling weights were obtained from Antoniou and colleagues
[1].
Cox proportional hazards regression was used to model the
time from birth to diagnosis of breast cancer. In this model, the
hazard or instantaneous probability of breast cancer diagnosis
is modeled as a function of the predictor covariates. The rela-
tive risk or hazard ratio (HR) is then interpreted for each cov-
ariate as the proportionate change in the instantaneous
probability of diagnosis for two individuals, differing only by a
single unit of that covariate. When analyzing LD blocks with
multiple SNPs, an additive haplotype effect was assumed
where the most common haplotype was used as the referent
group for comparisons. When an LD block consisted of a sin-
gle SNP, however, a general genetic model making no additiv-
ity assumption was used. In order to account for phase
uncertainty in haplotype analysis, we used a two-step approx-
imation to the semiparametric maximum likelihood estimator of
Lin and Zeng [25]. Using this method, the expectation-maximi-
zation algorithm was used to compute posterior estimates of
the probability of all potential haplotypes for a subject given
their known genotype, and these probabilities were used to
weight the individual's contribution to the partial likelihood. A
similar approach has previously been applied to logistic
regression models for analyzing case-control data and was
shown to provide robust inference for relatively common hap-
lotypes with little phase ambiguity [26]. In order to account for
hierarchical clustering at the individual level (multiple records
per individual were analyzed according to the number of
potential diplotypes consistent with the individual's genotype)
and at the family level (matched controls were often selected
from the family of a case), the sandwich estimator of Lin and
Wei [27] was used in combination with multiple outputation
[23] to obtain robust variance estimates of haplotype
associations.
All estimates were adjusted for birth cohort (to account for fre-
quency matching of cases and controls), race/ethnicity, parity,
and region of center (North American (US) vs. European).
Ashkenazi Jewish individuals were considered a separate eth-
nicity because the carriers only had one of three founder muta-
tions. Parity, prophylactic oophorectomy, and ovarian cancer
status were treated as time-dependent covariates in the anal-
ysis, with these covariates updated at the time of childbirth.
Beyond adjustment for birth cohort, no additional weighting for
selection was employed. For LD blocks exhibiting significant
associations with the time to breast cancer diagnosis, second-
ary analyses of individual SNPs making up the LD block were
conducted. For all analyses, the proportional hazards assump-
tion was examined by considering multiplicative interactions
between each haplotype (or SNP) of interest and (log-trans-
formed) time. No significant departures from the proportional
hazards assumption were observed.
In total, the current analysis involves testing of 48 LD blocks,
which is likely to result in an inflation of the family-wise type I
error rate for the study if unadjusted critical values are used for
assessing LD block significance. Noting that this analysis rep-
resents a first-stage in identifying variants in the IGF pathway
that are associated with time to breast cancer diagnosis, we
sought to control the family-wise type error rate at 15% in
order to minimize the type II error rate, limiting the possibility of
ruling out potentially important LD blocks from future investiga-
tion. Simulation was used to estimate the family-wise type I
error rate, assuming a correlation of 0.75 across tests was
assumed. Based upon 100,000 simulations it was estimated
that an adjusted P value of 0.016 on any individual LD block
test would result in a family-wise type I error rate of 15% for
the study. An adjusted P < 0.016 was interpreted as a signifi-
cant association.
Results
The characteristics of the cases and the sites, and the
observed incidence rate (per 1,000 women per year) of breast
cancer diagnosis stratified by BRCA status are presented in
Table 1. The presented rates have been externally standard-
ized to the age distribution of the study cohort at the time of
genetic testing. The study included 1,222 BRCA1 carriers
(433 diagnosed with breast cancer) and 543 BRCA2 carriers
(238 diagnosed with breast cancer). The age-standardized
Figure 1
Kaplan-Meier estimates of the cumulative probability of breast cancer di gnosis by BRCA status
diagnosis by BRCA status.  Statistics in the lower portion of the plot 
represent the number of patients at risk (cumulative number of diag-
noses) at each decade of life, ranging from 20 to 80 years. Estimates 
are weighted to account for oversampling of cases to controls [1].Page 5 of 12
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26.94 per 1,000 per year in BRCA1 carriers (95% confidence
interval (CI) = 19.79, 34.10) compared with 25.03 per 1,000
per year in BRCA2 carriers (95% CI = 18.71, 31.36). The
majority of study subjects in both strata were White Caucasian
(non-Jewish, non-Hispanic). Of the study subjects, 9.5%
underwent bilateral prophylactic mastectomy (107/1,122
among BRCA1 carriers and 40/543 among BRCA2 carriers)
and 39.4% underwent prophylactic bilateral salpingo-
oophorectomy (449/1,122 among BRCA1 carriers and 207/
543 among BRCA2 carriers). Figure 1 shows the estimated
cumulative probabilities of breast cancer diagnosis in BRCA1
and BRCA2 carriers observed in the study. The median age at
diagnosis was estimated to be 57.0 years (95% CI = 54.1,
62.2) among BRCA1 carriers and was 70.5 years (95% CI =
67.7, INF) among BRCA2 carriers.
IGF binding proteins IGFBP1, IGFBP2, and IGFBP5
Figure 2 presents the estimated HR for time to diagnosis by
LD block within each of the IGFBPs, and the BRCA status
after adjustment for covariates (described in Materials and
methods). For BRCA1 carriers, no significant associations
were observed for the three IGF binding genes. Among
BRCA2 carriers, one LD block in IGFBP2 showed signifi-
cance in the hazard for diagnosis. For IGFBP2 LD block 2
(defined by a single SNP rs9341134), women with at least
one variant allele were estimated to experience a 41% lower
risk of diagnosis when compared with women with no variant
Figure 2
Haplotype presence for insulin-like growth factor binding proteins.  Estimated hazard ratios (Est HR) associated with haplotype presence for (a) 
insulin-like growth factor binding protein (IGFBP)-1, (b) IGFBP2, and (c) IGFBP5. Linkage blocks were defined as pairwise linkage disequilibrium 
coefficient D' ≥ 0.90. Estimates were stratified by BRCA status (left column, BRCA1; right column, BRCA2) and adjusted for birth cohort and eth-
nicity as well as first pregnancy, prophylactic oophorectomy, and diagnosis of ovarian cancer as time-dependent covariates. LD Grp, linkage disequi-
librium group; Geno/Haplo, genotype/haplotype; Freq, frequency.Page 6 of 12
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Haplotype presence for insulin-like growth factor receptor substrate 1 and insulin-like growth factor 1li .  Estimated hazard ratios (Est HR) associated 
with haplotype presence for (a) insulin-like growth factor receptor substrate 1 (IRS1) and (b) insulin-like growth factor 1 (IGF1). Linkage blocks were 
defined as in Figure 2 (pairwise linkage disequilibrium coefficient D' ≥ 0.90). Estimates were stratified by BRCA status (left column, BRCA1; right 
column, BRCA2) and adjusted for birth cohort and ethnicity as well as first pregnancy, prophylactic oophorectomy, and diagnosis of ovarian cancer 
as time-dependent covariates. LD Grp, linkage disequilibrium group; Geno/Haplo, genotype/haplotype; Freq, frequency.
alleles (HR = 0.59; 95% CI = 0.39, 0.90; unadjusted global P
= 0.0145). For IGFBP5 LD block 2 (defined by a single SNP
rs2241193), women with at least one variant allele were esti-
mated to experience a 29% lower risk of diagnosis when com-
pared with women with no variant alleles (HR = 0.71; 95% CI
= 0.53, 0.96; unadjusted global P = 0.0242).
Insulin-like growth factor receptor substrate 1 and 
insulin-like growth factor 1
Estimated HRs for the haplotypes of IRS1 are shown in Figure
3a. Among BRCA1 carriers, the global LD block test for IRS1
was not significant (unadjusted global P = 0.0551). Relative
to the referent haplotype, however, individuals with haplotypes
homozygous for the common variant (excluding haplotypes
001 and 100) were estimated to have a 43% (CI = 1.06, 1.95;
P = 0.02) higher risk of breast cancer diagnosis.
We then investigated the HRs for the three SNPs within the
LD block to determine whether the observed haplotype asso-
ciations were attributable to particular SNPs (Table 2). For
SNPs rs13306465 and rs1801123, individuals carrying at
least one variant allele experienced a 44% (HR = 1.44; 95%
CI = 1.07, 1.94; unadjusted P = 0.0165) and 37% (HR =
1.37; 95% CI = 1.11, 1.69; unadjusted P = 0.0033) higher
risk of breast cancer relative to wild-type carriers, respectively.
There was no individual association of the rs1801278
(G972R) SNP and risk. For the single IRS1 LD block, a similar,
but nonsignificant HR of 1.52 (95% CI = 0.99, 2.32; unad-
justed P = 0.055) was observed in BRCA2 carriers.
For IGF1, no significant associations were found for either
BRCA1 or BRCA2 carriers (Figure 3b).
Insulin-like growth factor-1 receptor
Figure 4 shows HR estimates for the 12 LD blocks genotyped
in IGF1R. For BRCA1 carriers, significant associations were
found between LD block 2 (SNP rs2715415) and LD block 11
and the risk of breast cancer diagnosis (unadjusted global P
values corresponding to a test of homogeneity of risk within
the LD blocks were 0.011 for LD block 2 and 0.012 for LD
block 11). While qualitatively consistent associations were
also observed among BRCA2 carriers, they were not signifi-
cant. After investigation in BRCA1 carriers of the individual
SNPs within LD block 11 (Table 2), the only SNP that was sig-
nificantly associated with risk was rs8038415 - in which indi-
viduals homozygous for the variant allele were estimated toPage 7 of 12
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Single SNP analysis results within significant linkage disequilibrium blocks for BRCA1 carriers
LD blocka SNP Genotype n Hazard ratio 95% confidence interval P for trend
IRS1 1 rs1801278 GG 990
GA, AA 115 0.82 0.58, 1.17
1 rs13306465 GG 999
GA, AA 97 1.44 1.07, 1.94
1 rs1801123 AA 823
AG, GG 279 1.37 1.11, 1.69
IGF1R 11 rs8038415 CC 281
CT 536 1.11 0.88, 1.41
TT 270 1.40 1.07, 1.83 0.015
11 rs17847201 GG 350
GA 581 0.87 0.69, 1.10
AA 154 0.77 0.56, 1.05 0.091
IRS1, insulin-like growth factor receptor substrate 1; IGF1R, insulin-like growth factor-1 receptor. aLinkage disequilibrium (LD) block was defined 
by pairwise LD coefficient D' ≥ 0.90.
experience a 40% higher risk of breast cancer diagnosis
(unadjusted P = 0.014, with P for trend = 0.015).
Discussion
The IGF pathway plays essential roles in regulating cell prolif-
eration, differentiation, and apoptosis. It is a key factor in the
development and progression of breast cancer, based on evi-
dence from more than 1,100 published papers, ranging from
in vivo and in vitro studies in humans and mice to epidemio-
logic studies (reviewed in [14-16]). This is the first study to
investigate the role of genetic variants in IGF signaling as mod-
ifiers of breast cancer risk in women who carry deleterious
mutations in BRCA1 and BRCA2. We investigated only a
small number of the genes involved in IGF signaling. We found
significant HRs associated with genetic variants in IGF1R and
IRS1 in BRCA1 carriers, and in IGFBP2 in BRCA2 carriers.
No other significant associations in the studied genes were
identified.
There have been a limited number of epidemiologic studies of
the association of sporadic breast cancer risk and genetic var-
iation in genes in the IGF pathway. For IGF1, the primary lig-
and for the IGF1R, there have been inconsistent reports of
associations with breast cancer risk with reports showing sig-
nificant associations [28,29] and no associations [30-35]. The
inconsistent results may be due to differences in genetic vari-
ants examined in the genes and/or in study design (for exam-
ple, restriction to postmenopausal or premenopausal breast
cancers). Several studies of SNPs in IGFBP1 reported no
association with breast cancer, similar to what we observed
for BRCA1 and BRCA2 mutation carriers [28,35,36].
The IGFBPs serve as growth modulators, both independently
and as regulators of IGFs [37-39]. IGFBP5 and IGFBP2 are
overexpressed in breast cancer tissues [40,41], and are
involved in apoptosis [42-44]. In a study of African Americans,
with replication in Nigerians, we reported significant associa-
tions of SNPs within the IGFBP2 to IGFPB5 region and the
risk of breast cancer [45]. These two genes are in a tail-to-tail
configuration separated by only 10 kb on chromosome 2q, so
it is possible the same underlying causal variation results in an
association with both genes. In the present study, we report a
significant association of IGFBP2 SNP rs9341134, also
observed in the previous study [45], and marginally significant
associations with variants in IGFBP5. Resequencing is
needed to try to identify the actual causal variant. Another
piece of evidence that this region may be associated with
breast cancer is the association of SNP rs13387042 with a
1.2-fold increased risk in breast cancer, reported in a
deCODE genome-wide association study [46] - with replica-
tion by the Cancer Genetic Markers of Susceptibility project
(odds ratio = 1.2) [47], by the Breast Cancer Association
Consortium (odds ratio = 1.14) [48], and by the Consortium
of Investigators of Modifiers of BRCA1 and BRCA2 (HR =
1.14 and HR = 1.18 for BRCA1 and BRCA2 carriers, respec-
tively) [49]. It is hypothesized that this SNP may act as a long-
range regulatory element on expression of IGFBP2 or IGFBP5
[46].
Of the genes examined, only genetic variants in IGF1R and its
adaptor protein IRS1 were associated with risk of breast can-
cer in BRCA1 carriers. IGF1R has both mitogenic and antiap-
optotic roles in tumor development via signaling through thePage 8 of 12
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kinase pathways [50], with its adaptor protein IRS1 critical in
activating the downstream pathways. Both IGF1R overexpres-
sion and IRS1 overexpression have been associated with
breast cancer development, and IGF1R is overexpressed in a
majority of breast tumors [51]. Interestingly, BRCA1 directly
affects IGF1 signaling. In multiple experimental systems
including primary mammary tumors, cultured human cells, and
Brca1-deficient mice, Shukla and colleagues showed that
BRCA1 deficiency resulted in increased expression of IRS1,
IGF1R and IGFBP2, and increased levels of serum IGF1 [19].
In another study investigating IGF1R levels in breast tumors,
there were significantly higher levels of IGF1R in tumors from
BRCA1 mutation carriers as compared with noncarriers [20].
In a series of experiments co-transfecting cell lines with IGF1R
promoter constructs driving luciferase reporter genes, and a
BRCA1 expression vector, it was shown that BRCA1 sup-
pressed IGF1R promoter activity in a dose-dependent manner
[52], through preventing binding of Sp1 to the IGF1R pro-
moter, thus reducing transcription [52,53]. As demonstrated
using western blots, wild-type BRCA1 was able to induce a
large reduction in endogenous IGF1R levels [20]. In addition
to its interaction with the IGF1R, BRCA1 interacts directly
with the IRS1 promoter to inhibit its activity [19]. With induc-
tion of BRCA1, the authors observed a twofold and threefold
decrease of IRS1 mRNA and protein levels, respectively, as
well as a decrease in the phosphorylation level of AKT, a
downstream target of IGF1R and IRS1 [19].
Figure 4
Haplotype presence for insulin-like growth factor-1 receptor.  Estimated hazard ratios (Est HR) associated with haplotype presence for insulin-like 
growth factor-1 receptor (IGF1R). Linkage blocks were defined as in Figure 2 (pairwise linkage disequilibrium coefficient D' ≥ 0.90). Estimates were 
stratified by BRCA status (left column, BRCA1; right column, BRCA2) and adjusted for birth cohort and ethnicity as well as first pregnancy, prophy-
lactic oophorectomy, and diagnosis of ovarian cancer as time-dependent covariates. LD Grp, linkage disequilibrium group; Geno/Haplo, genotype/
haplotype; Freq, frequency.Page 9 of 12
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mutant forms of BRCA1 cause increased IGF1R activation,
leading to a decrease in apoptosis and a concomitant
increased survival of malignant cells, which then can prolifer-
ate. There is therefore a strong rationale for why genetic varia-
tion in IGF1R and IRS1 would be important in breast cancer
risk in BRCA1 carriers. Experimental studies have not been
published for BRCA2 to demonstrate whether there is a simi-
lar effect on transcriptional regulation.
As noted above, this is the first study to investigate the role of
genetic variants in IGF signaling as modifiers of breast cancer
risk in women who carry deleterious mutations in BRCA1 and
BRCA2. While the study does provide an important first step
in identifying potential genetic modifiers of risk among BRCA1
and BRCA2 carriers, it does suffer some limitations. First,
although the IGF pathway was hypothesized a priori as a
source for potential modifiers, multiple LD blocks were consid-
ered for association testing and such testing could lead to
inflation of the overall type I error rate for the study. With this
said, we only studied a small number of the genes in IGF sig-
naling that we deemed a priori would potentially play a role in
the time to diagnosis. Further, the goal of the current research
was to generate hypotheses based upon the results from this
well-defined set of genes, and it is our intention to further vali-
date these results using an independent sample. As with all
observational studies, there is the potential for selection bias
and unmeasured confounding. We have, however, adjusted
for those environmental factors that previous research has
shown to most highly influence the risk of breast cancer diag-
nosis within this cohort, thus lowering the potential for unad-
justed confounding.
We and others have investigated putative risk factors, and a
number of published studies have implicated candidate genes
(for example, AIB1 in BRCA1, RAD51 in BRCA2) and SNPs
in FGFR2, MAP3K1, TNRC9, LSP1, and 2q35 previously
identified from genome-wide association studies of breast
cancer as modifiers of breast cancer or ovarian cancer pene-
trance in women who carry germline BRCA1 or BRCA2 muta-
tions [9-13,49]. Our results suggest that variation in genes in
IGF signaling also modify breast cancer penetrance in BRCA1
and BRCA2 carriers.
Conclusions
The present study is the first to investigate the role of genetic
variation in IGF signaling and breast cancer risk in women car-
rying deleterious mutations in BRCA1 and BRCA2. We iden-
tified significant associations for variants in IGF1R and IRS1
for BRCA1 carriers and for variants in IGFBP2 for BRCA2
carriers. Given the known interaction of BRCA1 and IGF sign-
aling, and specifically the regulation of IRS1 and IGF1R by
BRCA1, further replication and identification of causal mecha-
nisms are needed to validate and better understand these
associations.
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